Lotsof, who died earlier this year of liver cancer at age 66, devoted his life to making ibogaine available as an addiction treatment. He experienced a significant setback in 1967, when the U.S. government banned the drug, along with several other psychedelics. In 1970, officials categorized ibogaine as a Schedule I substance — on par with heroin, marijuana, and other drugs that by definition have "a high potential for abuse" and "no currently accepted medical use."

Eventually Lotsof shifted his focus and began using ibogaine to treat heroin addicts at a rehab clinic in the Netherlands. In 1985, he obtained a U.S. patent for the use of ibogaine to treat substance abuse. By the late '80s, doctors and scientists were confirming what Lotsof knew: Ibogaine blocks cravings and withdrawal symptoms for many types of drugs, and opiates in particular.

"Its effects are pretty dramatic," says Kenneth Alper, an associate professor of psychiatry at New York University who specializes in addiction research. "I've observed this firsthand, and it's difficult to account for." Stanley Glick, a pharmacologist and neuroscientist at Albany Medical College, was among the first researchers to test ibogaine on rats. He hooked up the rodents to IVs in cages with levers that allowed them to inject themselves with morphine. "If the rats do it, you can be pretty sure that humans will abuse it if given the opportunity," he says. "It's really the time-tested model of any human behavior."

Pangea Biomedics is located in a lavish home in Tijuana’s Playas neighborhood.
Keegan Hamilton
Pangea Biomedics is located in a lavish home in Tijuana’s Playas neighborhood.
Tom Kingsley Brown, a researcher from UC San Diego, is studying whether ibogaine works long term to quell addiction.
Keegan Hamilton
Tom Kingsley Brown, a researcher from UC San Diego, is studying whether ibogaine works long term to quell addiction.

Strung-out rats dosed with ibogaine stopped pressing the lever that gave them morphine. Glick and other researchers have subsequently replicated the morphine results with other addictive drugs, including alcohol, nicotine, cocaine, and methamphetamine.In the early 1990s, Lotsof teamed with Deborah Mash, a neurologist and pharmacologist at the University of Miami, to study the effect of ibogaine on people. She was granted FDA approval to administer ibogaine in 1993 and was able to test the drug on eight people before the experiment came to an abrupt halt. "I was unable to get it funded," she says. "We had the rocket ship on the launch pad, with no fuel."

A few months after the FDA gave Mash the green light, a committee of academics and pharmaceutical-industry professionals assembled by the National Institute on Drug Abuse (NIDA) concluded that the U.S. government should not fund ibogaine research. Earlier that year, a researcher from Johns Hopkins University had found that rats injected with massive doses of ibogaine suffered irreparable damage to the cerebellum, the part of the brain that controls balance and motor skills. According to Frank Vocci, former director of treatment research and development at NIDA, the fact that ibogaine increases the risk of seizures for people addicted to alcohol or benzodiazepines such as Valium raised eyebrows as well.

"The question that was posed to them was, 'Do you think that this could be a project that could result in, essentially, a marketable product?'" Vocci recalls. "There was concern about brain damage, seizures, and heart rate. But it wasn't so much that the ultimate safety of the drug was being damned — it was just felt that there were an awful lot of warts on this thing."

Mash and Lotsof soon parted ways, on unfriendly terms. Lotsof sued his former colleague and the University of Miami in federal court in 1996, claiming that her research had infringed on his patent. A judge eventually ruled in favor of Mash and her employer, absolving them of wrongdoing.

Lotsof went his own way, mentoring fellow former addicts who opened ibogaine rehab centers abroad. Mash opened a private clinic on the Caribbean island of St. Kitts and administered ibogaine to nearly 300 addicts. "It really works," she says now. "If it didn't work, I would have told the world it doesn't work. I would have debunked it, and I would have been the most outspoken leader of the pack. That's my scientific and professional credibility on the line."


Clare Wilkins is one of Howard Lotsof's protégées. Born in South Africa and raised in Los Angeles, she got hooked on heroin at age 20 while majoring in Latin American studies and psychology at Cornell University. Drug use led to depression and she dropped out her senior year. She'd been trying to get clean using methadone for eight and a half years when her younger sister learned about ibogaine via the Internet. Wilkins, then 30 and employed as bookkeeper, read up on the subject, started saving, and in 2005 shelled out $3,200 for a session at the Ibogaine Association, a clinic in Tijuana.

The trip — in both senses of the word — changed her life.

"I received a direct message that I was washed in love," she says of her first encounter with the hallucinogen. "That the universe in its entirety is full of love and that courses through us and was there for me. There was this soul body, this light body that had no beginning and no end. My fingers had no end, there were atoms coming in and going out.

"It got me off of methadone completely," she says. "My sense of shame about my addiction was washed away without having to practice with a therapist and talk, talk, talk."

« Previous Page
 |
 
1
 
2
 
3
 
4
 
5
 
6
 
All
 
Next Page »
 
My Voice Nation Help
0 comments
 
©2014 SF Weekly, LP, All rights reserved.
Loading...